These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

208 related articles for article (PubMed ID: 24685542)

  • 1. Purine derivatives as potent Bruton's tyrosine kinase (BTK) inhibitors for autoimmune diseases.
    Shi Q; Tebben A; Dyckman AJ; Li H; Liu C; Lin J; Spergel S; Burke JR; McIntyre KW; Olini GC; Strnad J; Surti N; Muckelbauer JK; Chang C; An Y; Cheng L; Ruan Q; Leftheris K; Carter PH; Tino J; De Lucca GV
    Bioorg Med Chem Lett; 2014 May; 24(9):2206-11. PubMed ID: 24685542
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Design and synthesis of novel pyrimidine analogs as highly selective, non-covalent BTK inhibitors.
    Kawahata W; Asami T; Irie T; Sawa M
    Bioorg Med Chem Lett; 2018 Jan; 28(2):145-151. PubMed ID: 29198867
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Imidazo[1,5-a]quinoxalines as irreversible BTK inhibitors for the treatment of rheumatoid arthritis.
    Kim KH; Maderna A; Schnute ME; Hegen M; Mohan S; Miyashiro J; Lin L; Li E; Keegan S; Lussier J; Wrocklage C; Nickerson-Nutter CL; Wittwer AJ; Soutter H; Caspers N; Han S; Kurumbail R; Dunussi-Joannopoulos K; Douhan J; Wissner A
    Bioorg Med Chem Lett; 2011 Nov; 21(21):6258-63. PubMed ID: 21958547
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bruton's TK inhibitors: structural insights and evolution of clinical candidates.
    Xing L; Huang A
    Future Med Chem; 2014 Apr; 6(6):675-95. PubMed ID: 24895895
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Discovery of 6-Fluoro-5-(R)-(3-(S)-(8-fluoro-1-methyl-2,4-dioxo-1,2-dihydroquinazolin-3(4H)-yl)-2-methylphenyl)-2-(S)-(2-hydroxypropan-2-yl)-2,3,4,9-tetrahydro-1H-carbazole-8-carboxamide (BMS-986142): A Reversible Inhibitor of Bruton's Tyrosine Kinase (BTK) Conformationally Constrained by Two Locked Atropisomers.
    Watterson SH; De Lucca GV; Shi Q; Langevine CM; Liu Q; Batt DG; Beaudoin Bertrand M; Gong H; Dai J; Yip S; Li P; Sun D; Wu DR; Wang C; Zhang Y; Traeger SC; Pattoli MA; Skala S; Cheng L; Obermeier MT; Vickery R; Discenza LN; D'Arienzo CJ; Zhang Y; Heimrich E; Gillooly KM; Taylor TL; Pulicicchio C; McIntyre KW; Galella MA; Tebben AJ; Muckelbauer JK; Chang C; Rampulla R; Mathur A; Salter-Cid L; Barrish JC; Carter PH; Fura A; Burke JR; Tino JA
    J Med Chem; 2016 Oct; 59(19):9173-9200. PubMed ID: 27583770
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The development of Bruton's tyrosine kinase (BTK) inhibitors from 2012 to 2017: A mini-review.
    Liang C; Tian D; Ren X; Ding S; Jia M; Xin M; Thareja S
    Eur J Med Chem; 2018 May; 151():315-326. PubMed ID: 29631132
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antiarthritis effect of a novel Bruton's tyrosine kinase (BTK) inhibitor in rat collagen-induced arthritis and mechanism-based pharmacokinetic/pharmacodynamic modeling: relationships between inhibition of BTK phosphorylation and efficacy.
    Liu L; Di Paolo J; Barbosa J; Rong H; Reif K; Wong H
    J Pharmacol Exp Ther; 2011 Jul; 338(1):154-63. PubMed ID: 21521773
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Design, synthesis and biological evaluation of 7H-pyrrolo[2,3-d]pyrimidin-4-amine derivatives as selective Btk inhibitors with improved pharmacokinetic properties for the treatment of rheumatoid arthritis.
    He L; Pei H; Zhang C; Shao M; Li D; Tang M; Wang T; Chen X; Xiang M; Chen L
    Eur J Med Chem; 2018 Feb; 145():96-112. PubMed ID: 29324347
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Structure-activity relationship investigation for benzonaphthyridinone derivatives as novel potent Bruton's tyrosine kinase (BTK) irreversible inhibitors.
    Wang B; Deng Y; Chen Y; Yu K; Wang A; Liang Q; Wang W; Chen C; Wu H; Hu C; Miao W; Hur W; Wang W; Hu Z; Weisberg EL; Wang J; Ren T; Wang Y; Gray NS; Liu Q; Liu J
    Eur J Med Chem; 2017 Sep; 137():545-557. PubMed ID: 28628824
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Discovery of novel Bruton's tyrosine kinase (BTK) inhibitors bearing a pyrrolo[2,3-d]pyrimidine scaffold.
    Zhao X; Huang W; Wang Y; Xin M; Jin Q; Cai J; Tang F; Zhao Y; Xiang H
    Bioorg Med Chem; 2015 Feb; 23(4):891-901. PubMed ID: 25596757
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Design and synthesis of carbazole carboxamides as promising inhibitors of Bruton's tyrosine kinase (BTK) and Janus kinase 2 (JAK2).
    Liu Q; Batt DG; Lippy JS; Surti N; Tebben AJ; Muckelbauer JK; Chen L; An Y; Chang C; Pokross M; Yang Z; Wang H; Burke JR; Carter PH; Tino JA
    Bioorg Med Chem Lett; 2015 Oct; 25(19):4265-9. PubMed ID: 26320619
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fragment-Based Discovery of a Small Molecule Inhibitor of Bruton's Tyrosine Kinase.
    Smith CR; Dougan DR; Komandla M; Kanouni T; Knight B; Lawson JD; Sabat M; Taylor ER; Vu P; Wyrick C
    J Med Chem; 2015 Jul; 58(14):5437-44. PubMed ID: 26087137
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Potent and selective Bruton's tyrosine kinase inhibitors: discovery of GDC-0834.
    Young WB; Barbosa J; Blomgren P; Bremer MC; Crawford JJ; Dambach D; Gallion S; Hymowitz SG; Kropf JE; Lee SH; Liu L; Lubach JW; Macaluso J; Maciejewski P; Maurer B; Mitchell SA; Ortwine DF; Di Paolo J; Reif K; Scheerens H; Schmitt A; Sowell CG; Wang X; Wong H; Xiong JM; Xu J; Zhao Z; Currie KS
    Bioorg Med Chem Lett; 2015 Mar; 25(6):1333-7. PubMed ID: 25701252
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Finding the perfect spot for fluorine: improving potency up to 40-fold during a rational fluorine scan of a Bruton's Tyrosine Kinase (BTK) inhibitor scaffold.
    Lou Y; Sweeney ZK; Kuglstatter A; Davis D; Goldstein DM; Han X; Hong J; Kocer B; Kondru RK; Litman R; McIntosh J; Sarma K; Suh J; Taygerly J; Owens TD
    Bioorg Med Chem Lett; 2015 Jan; 25(2):367-71. PubMed ID: 25466710
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bruton's tyrosine kinase as a molecular target in treatment of leukemias and lymphomas as well as inflammatory disorders and autoimmunity.
    Uckun FM; Qazi S
    Expert Opin Ther Pat; 2010 Nov; 20(11):1457-70. PubMed ID: 20831363
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bruton's tyrosine kinase inhibitors for the treatment of rheumatoid arthritis.
    Whang JA; Chang BY
    Drug Discov Today; 2014 Aug; 19(8):1200-4. PubMed ID: 24721226
    [TBL] [Abstract][Full Text] [Related]  

  • 17. RN486, a selective Bruton's tyrosine kinase inhibitor, abrogates immune hypersensitivity responses and arthritis in rodents.
    Xu D; Kim Y; Postelnek J; Vu MD; Hu DQ; Liao C; Bradshaw M; Hsu J; Zhang J; Pashine A; Srinivasan D; Woods J; Levin A; O'Mahony A; Owens TD; Lou Y; Hill RJ; Narula S; DeMartino J; Fine JS
    J Pharmacol Exp Ther; 2012 Apr; 341(1):90-103. PubMed ID: 22228807
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Synthesis and biological evaluation of novel 7-substituted 3-(4-phenoxyphenyl)thieno[3,2-c]pyridin-4-amines as potent Bruton's tyrosine kinase (BTK) inhibitors.
    Xin M; Zhao X; Huang W; Jin Q; Wu G; Wang Y; Tang F; Xiang H
    Bioorg Med Chem; 2015 Oct; 23(19):6250-7. PubMed ID: 26344595
    [TBL] [Abstract][Full Text] [Related]  

  • 19. TR-FRET binding assay targeting unactivated form of Bruton's tyrosine kinase.
    Asami T; Kawahata W; Sawa M
    Bioorg Med Chem Lett; 2015; 25(10):2033-6. PubMed ID: 25872980
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ability of Bruton's Tyrosine Kinase Inhibitors to Sequester Y551 and Prevent Phosphorylation Determines Potency for Inhibition of Fc Receptor but not B-Cell Receptor Signaling.
    Bender AT; Gardberg A; Pereira A; Johnson T; Wu Y; Grenningloh R; Head J; Morandi F; Haselmayer P; Liu-Bujalski L
    Mol Pharmacol; 2017 Mar; 91(3):208-219. PubMed ID: 28062735
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.